hotspot -WSS

hotspot

author：Wikipedia 2025-09-28 02:28:55 - browse：69536

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： DeSantis can now import cheaper drugs. But will Biden get credit?

focus

explore

WSS

Free Covid tests will again be offered to all U.S. households

Information blocking fines are now fair game in health care

Information blocking fines are now fair game in health care

Covid’s new normal has set in amid another rise in cases

Covid’s new normal has set in amid another rise in cases

House panel takes first step toward fixing drug shortages

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Designating disabled people as health disparity population is crucial

BioMarin wins approval for gene therapy to treat hemophilia A

Chamber of Commerce, DOJ clash in court over drug prices

United colonoscopy coverage change 'may cost lives,' doctors say

Generative AI mines health records to identify patients’ social needs

Duchenne breakthrough therapy leaves behind pioneering families

Heart disease and mental health: A look at cardiac psychology

Cancer drug shortages should be causing more outrage

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

focus

The SUPPORT Act is critical to fighting the opioid crisis

'A game

David Liu startup to focus on CRISPR delivery

Midwives could help bridge maternal health disparities in the U.S.

The unintended consequences of overturning Roe v. Wade

Assistant physicians can help address the primary care shortage

entertainment

focus

explore

Wikipedia